

Clinicopathological Characteristics and Survival Outcomes in Mammary Paget's Disease: a Retrospective Study Based on a Chinese Population

Bo-yue Han

Fudan University Shanghai Cancer Center, Fudan University

Xiao-li Xu

Fudan University Shanghai Cancer Center, Fudan University

Xiu-zhi Zhu

Fudan University Shanghai Cancer Center, Fudan University

Xiang-chen Han

Fudan University Shanghai Cancer Center, Fudan University, .\n University

Xin Hu

Fudan University Shanghai Cancer Center, Fudan University, .\n University

Hong Ling (✉ linghong98@aliyun.com)

Fudan University Shanghai Cancer Center, Fudan University

Research Article

Keywords: Mammary Paget's disease (PD), survival outcomes, Clinicopathological characteristics, Chinese population, Breast cancer

Posted Date: May 28th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-523681/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Cancer Management and Research on January 1st, 2022. See the published version at <https://doi.org/10.2147/CMAR.S338788>.

Abstract

Background: Mammary Paget's disease (PD) is a rare type of breast cancer. Most cases of PD is presented with underlying ductal carcinoma in situ (DCIS) or invasive breast carcinoma (IDC). This study aimed to investigate the clinicopathological characteristics and survival outcomes of PD patients.

Materials and Methods: A total of 406 patients diagnosed with PD with IDC/DCIS at Fudan University Shanghai Cancer Center (FUSCC) were recruited as the PD group, 1218 patients diagnosed with IDC/DCIS alone during the same period were selected as the non-PD group, and the clinicopathological results of these two groups were compared. The Surveillance, Epidemiology, and End Results (SEER) database was used to investigate the clinicopathological features between PD and non-PD patients for validation. Then, a matched group study was performed to compare the survival of PD and non-PD patients.

Results: Compared with the non-PD group, the PD group was much more likely to have larger (≥ 2 cm: 43.1% vs. 35.5%, $P < 0.001$), less hormone receptor (HR)-positive (68.5% vs. 26.6%, $P < 0.001$), more human epidermal growth factor receptor-2 (HER-2)-positive (70.7% vs. 27.5%, $P < 0.001$) and higher Ki-67 proportion (51.5% vs. 42.5%, $P < 0.001$) tumors. The HER-2 overexpression subtype accounted for the largest proportion in the PD-IDC group and the lowest proportion in the non-PD-IDC group (54% vs. 8%, $P < 0.01$). Moreover, the PD group had significantly worse disease-free survival (DFS) than the non-PD group (5-year DFS: 91.8% vs. 97.3%, $P = 0.001$), and the SEER database showed a similar trend. Univariate and multivariate Cox regression analyses demonstrated that PD was an independent poor-risk factor for breast cancer survival. Our matched study showed that the PD group had worse survival than the non-PD group after excluding age, HR, HER-2, tumor size and lymph node status.

Conclusions: PD with IDC/DCIS is associated with more aggressive tumor characteristics and worse survival outcomes. More than half of PD breast cancers are of the HER-2 overexpression subtype. PD is an independent poor-risk factor for breast cancer survival.

Background:

Breast cancer is the most common cancer among women worldwide [1]. Mammary Paget's disease (PD) is a rare type of breast cancer. The incidence of this rare abnormality has been reported to be 0.5%-5% of all breast cancers [2, 3]. PD is clinically characterized by eczematoid eruption on the nipple and areola, accompanied by other skin changes such as itching, erythema, bloody nipple discharge, nipple erosion or ulceration, and nipple retraction [4]. Infiltration of malignant mammary epithelial cells on the nipple epidermis is the main pathological change in PD [5]. Approximately 90% of mammary PD cases present with underlying ductal carcinoma in situ (DCIS) or invasive breast carcinoma (IDC); only a small proportion of PD cases involve skin changes alone [6].

The molecular subtype of breast cancer is distinguished by gene expression profiling into four subtypes: luminal A, luminal B, HER-2 overexpression and triple-negative breast cancer [7]. Breast cancer is a heterogeneous disease, and each subtype has distinct clinicopathological characteristics and survival

outcomes [8]. To date, most of the literature reports that luminal A breast cancer has the best prognosis and that triple-negative breast cancer has the worst prognosis [9–11]. Since PD is a rare disease, most studies have included limited numbers. Thus, we enrolled 406 women diagnosed as having PD with IDC/DCIS at Fudan University Shanghai Cancer Center (FUSCC) to study whether the presence of PD is associated with clinicopathological characteristics and survival outcomes with underlying IDC/DCIS (PD-IDC/PD-DCIS).

Materials And Methods:

Participant eligibility

Four hundred and six patients diagnosed with nipple–areolar PD with underlying IDC/DCIS between January 1, 2004, and December 31, 2015, at FUSCC were recruited as part of the study group (PD group). Controls (non-PD group, n=1218) diagnosed with IDC/DCIS without PD during the same period were randomly selected in a 3:1 ratio to patients in the non-PD group. Participants were excluded if any of the following criteria applied: (1) patients diagnosed with stage IV breast cancer or ductal or lobular atypical hyperplasia, sarcomas or phyllodes tumors; (2) patients with a previous or concomitant malignancy; (3) pregnant patients; or (4) patients with situations precluding long-term follow-up.

In addition, we obtained data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database collected between January 1, 2010, and December 31, 2015. We used the histopathology code of the 3rd edition of the International Classification of Oncology (ICD-O-3) to extract 444 patients diagnosed with PD-IDC (code 8541). A total of 253496 patients with nonspecific types of ductal carcinoma (ICD-O-3 code 8500) were obtained as the control group. Patients with unknown estrogen receptor (ER) and/or progesterone receptor (PR) or human epidermal growth factor receptor-2 (HER-2) status were excluded. This retrospective study was approved by the Ethics Committee Review Board of FUSCC (050432).

A matched group was selected by a propensity score matching model according to five variables: age, HR status, HER-2 status, tumor size and lymph node status. After matching, non-PD patients were randomly selected in a strict 3:1 ratio to patients in the PD group.

Data collection

To analyze the clinicopathological characteristics of the PD group, the study parameters were as follows: age at diagnosis; pathologic tumor size; lymph node status; histological grade; ER and PR status; expression of HER-2; and treatments (adjuvant chemotherapy, radiotherapy, endocrine therapy and target therapy). An ER- and/or PR-positive status was considered hormone receptor (HR)-positive.

Disease-free survival (DFS) was defined as the time between the first date of diagnosis and any locoregional recurrence, including ipsilateral breast, local/regional lymph nodes of the disease, any contralateral breast cancer, any distant metastasis of the disease, or any secondary malignancy,

whichever occurred first [12, 13]. Overall survival (OS) was defined as the time from random assignment until death as a result of any cause, and breast cancer-specific survival (BCSS) was defined as the time from random assignment to death caused by breast cancer [12, 13]. The time and site of the first detected relapse, and the time and cause of death were recorded via follow-up phone.

Molecular subtypes were based on St Gallen 2017 Guidelines [14]. Luminal A: HR+, HER-2 (-), Ki-67<14%; Luminal B: HR+, HER-2(-), Ki-67 \geq 14% or HR+, HER-2(+); HER-2 Overexpression: HR-, HER-2 (+); TNBC (Triple-negative breast cancer): ER-, PR-, HER-2(-).

Statistical methods

T tests were used to compare age between the PD group and the non-PD group. Pearson chi-square tests were used to compare other clinicopathological variables. OS, BCSS and DFS were compared between the two groups using the Kaplan-Meier method. Univariate and multivariate Cox regression analyses were performed to identify prognostic factors. A propensity score matching model was used to conduct the matched study. All tests were two-sided, and a P-value less than 0.05 was considered statistically significant. SPSS statistical software version 25.0 package (IBM Corporation, Armonk, NY, USA) and R software version 3.5.3. (The R Project for Statistical Computing, <https://www.r-project.org/>) were used for the calculations and analyses. The R packages “MatchIt”, “survminer”, “readr”, and “survival” with the appropriate libraries were used.

Results:

Clinicopathological characteristics

In total, 406 patients were diagnosed with mammary PD during the study period at FUSCC. The mean age at diagnosis was 52.3 years, with a range from 27 to 92 years. Of these recruited PD patients, 82% (n = 333) had concomitant IDC, and 18% (n = 73) had DCIS. Table 1 shows the clinicopathological characteristics between the PD group and the non-PD group. Patients in the PD group were older than non-PD patients (52.3 years vs. 50.5 years, P = 0.004). Compared with the non-PD group, the PD group tended to have larger tumors (\geq 2 cm: 43.1% vs. 35.5%, P < 0.001) and more lymph node metastases (39.6% vs. 37.1%, P = 0.043). In addition, the PD group was much more likely to have HR-negative (68.5% vs. 26.6%, P < 0.001), HER-2-positive (70.7% vs. 27.5%, P < 0.001) and high proportions of Ki-67 (51.5% vs. 42.5%, P < 0.001) tumors than the control patients in the non-PD group. The SEER database also demonstrated that the PD group tended to have larger tumors (\geq 2 cm: 49.8% vs. 41.6%, P < 0.001), more lymph node metastases (49.8% vs. 32.9%, P < 0.001), and a greater proportion of HR-negative (37.8% vs. 17.0%, P < 0.001) and HER-2-positive (59.2% vs. 15.3%, P < 0.001) tumors than the non-PD group (Table S1).

Table 1

Clinical characteristics of PD Group and Non-PD Group of FUSCC.

Patient Characteristics and Treatments	PD Group	Non-PD Group	p ^(b)
	n = 406	n = 1218	
	No. (%)	No.	
Age (mean)	52.3	50.5	0.004 ^(c)
Tumor size(cm)			< 0.001
< 2	223 (54.9%)	687 (56.4%)	
≥ 2	175 (43.1%)	432 (35.5%)	
Unknown	8 (2.0%)	99 (8.1%)	
Lymph node metastasis (for IDC)			
Yes	132 (39.6%)	413 (37.1%)	0.043
No	197 (59.2%)	693 (62.2%)	
Unknown	4 (1.2%)	8 (0.7%)	
HR ^(a)			< 0.001
Positive	128 (31.5%)	894 (73.4%)	
Negative	278 (68.5%)	324 (26.6%)	
HER-2			< 0.001
Positive	287 (70.7%)	335 (27.5%)	
Negative	57 (14.0%)	779 (64.0%)	
Unknown	62 (15.3%)	104 (8.5%)	
Ki-67			< 0.001
low (< 14%)	108 (26.6%)	620 (50.9%)	
high (≥ 14%)	209 (51.5%)	518 (42.5%)	

Abbreviations: PD: Paget's Disease; HR: Hormone Receptor; HER-2: Human Epidermal Growth Factor Receptor-2; IDC: Invasive Ductal Carcinoma; DCIS: Ductal Carcinoma In Situ;

(a): HR positive: ER (Estrogen Receptor) positive or/and PR (Progesterone Receptor) positive.

(b): Pearson Chi-square tests between PD Group And Non-PD Group.

(c): T tests were used to compare age between PD Group And Non-PD Group.

Patient Characteristics and Treatments	PD Group	Non-PD Group	p ^(b)
	n = 406	n = 1218	
	No. (%)	No.	
Unknown	89 (21.9%)	78 (6.4%)	
Grade			< 0.001
1	3 (0.7%)	49 (4.0%)	
2	80 (19.7%)	649 (53.3%)	
3	287 (70.7%)	382 (31.4%)	
Unknown	36 (8.9%)	138 (11.3%)	
Tumor Type			< 0.001
IDC	333 (82.0%)	1114 (91.5%)	
DCIS	73 (18.0%)	104 (8.5%)	
Adjuvant Chemotherapy			< 0.001
Yes	228 (56.2%)	838 (68.8%)	
No	111 (27.3%)	318 (26.1%)	
Unknown	67 (16.5%)	62 (5.1%)	
Radiotherapy			< 0.001
Yes	68 (16.7%)	400 (32.8%)	
No	269 (66.3%)	740 (60.8%)	
Unknown	69 (17.0%)	78 (6.4%)	
Endocrine therapy			< 0.001
Yes	92 (22.7%)	774 (63.5%)	
No	265 (65.3%)	370 (30.4%)	
Unknown	49 (12.1%)	74 (6.1%)	

Abbreviations: PD: Paget's Disease; HR: Hormone Receptor; HER-2: Human Epidermal Growth Factor Receptor-2; IDC: Invasive Ductal Carcinoma; DCIS: Ductal Carcinoma In Situ;

(a): HR positive: ER (Estrogen Receptor) positive or/and PR (Progesterone Receptor) positive.

(b): Pearson Chi-square tests between PD Group And Non-PD Group.

(c): T tests were used to compare age between PD Group And Non-PD Group.

Patient Characteristics and Treatments	PD Group	Non-PD Group	p ^(b)
	n = 406	n = 1218	
	No. (%)	No.	
Target therapy			< 0.001
Yes	79 (19.5%)	152 (12.5%)	
No	195 (48.0%)	999 (82.0%)	
Unknown	132 (32.5%)	67 (5.5%)	
Abbreviations: PD: Paget's Disease; HR: Hormone Receptor; HER-2: Human Epidermal Growth Factor Receptor-2; IDC: Invasive Ductal Carcinoma; DCIS: Ductal Carcinoma In Situ;			
(a): HR positive: ER (Estrogen Receptor) positive or/and PR (Progesterone Receptor) positive.			
(b): Pearson Chi-square tests between PD Group And Non-PD Group.			
(c): T tests were used to compare age between PD Group And Non-PD Group.			

Molecular subtypes

We compared the molecular subtypes between the 333 patients diagnosed as having PD with IDC (PD-IDC group) and 1114 patients diagnosed with IDC alone (non-PD-IDC group). Figure 1 demonstrates that HER-2 overexpression accounted for the largest proportion in the PD-IDC group, while in the non-PD-IDC group, the proportion of HER-2 overexpression was the lowest (54% vs. 8%, $P < 0.001$). The proportion of both TNBC and luminal breast cancer was much smaller in the PD-IDC group (TNBC: 4% in the PD-IDC group vs. 17% in the non-PD-IDC group, $P < 0.001$; luminal A: 5% in the PD-IDC group vs. 28% in the non-PD-IDC group, $P < 0.001$; luminal B: 22% in the PD-IDC group vs. 39% in the non-PD-IDC group, $P < 0.001$). A similar trend was observed in the SEER database. Fig. S1 shows that HR-negative and HER-2-positive breast cancer, which corresponds to the HER-2 overexpression subtype, accounted for more breast cancer cases in the PD group than in the non-PD group (29% vs. 5%, $P < 0.001$), while HR-negative and HER-2-negative breast cancer (TNBC, 6% vs. 11%, $P < 0.001$) accounted for fewer breast cancer cases.

Survival analysis

For all recruited patients at FUSCC, the median follow-up time was 72.6 months (range, 5-189 months). As shown in Fig. 2a, the PD group had significantly worse DFS than the non-PD group ($P=0.001$, 5-year DFS: 91.8% vs. 97.3%). The survival analysis of the SEER database showed a similar result (Fig. 2b): the PD group had significantly worse BCSS than the non-PD group ($P<0.001$, 5-year DFS: 85.1% vs. 91.3%). However, when we compared OS between the PD-FUCSS and PD-SEER groups, we found that the PD-FUSCC group had better survival (Fig. S2, $P<0.001$). Next, a subgroup analysis was performed. The PD-IDC group had worse DFS than the PD-DCIS group (Fig. S3a, $P=0.039$). For different molecular subtypes

in the PD-IDC group, the DFS of TNBC patients was the worst, while patients with HER-2-overexpression breast cancer survived best (Fig. 3a, $P=0.045$). Interestingly, the good prognosis of HER-2-overexpression breast cancer was only observed in patients who had used targeted therapy (Fig. 3b, 3c).

Prognostic significance

Univariate and multivariate Cox regression analyses were performed to test the predictive function of clinicopathological factors on DFS (Table 2). Univariate Cox regression analyses demonstrated that age, HR, tumor size, lymph node status and PD were related to poor outcomes in BC patients. After adjusting for confounding variables, PD was confirmed as an independent factor for DFS (adjusted HR, 1.647; 95% CI, 1.030-2.639; $P=0.037$). Other independent risk factors were age (adjusted HR, 1.595; 95% CI, 1.041-2.445; $P=0.032$), HR (adjusted HR, 0.518; 95% CI, 0.354-0.756; $P=0.001$), tumor size (adjusted HR, 1.275; 95% CI, 1.059-1.535; $P=0.010$) and lymph node status (adjusted HR, 3.261; 95% CI, 2.226-4.776; $P<0.001$). To further confirm that PD is an independent poor prognostic factor for breast cancer, we excluded variables such as age, HR, HER-2, tumor size and lymph node status by matching (Table. S3). Our matched study revealed that the PD group showed worse survival than the non-PD group ($P=0.022$, Fig. 4).

Table 2

Univariate and Multivariate Cox regression analyses for DFS time among PD and Non-PD Group of FUSCC.

Variable	Univariate			Multivariate		
	HR	95% CI	<i>P</i> value	HR	95% CI	<i>P</i> value
Age(year)			0.017			0.032
<40	1			1		
≥40	1.683	1.098-2.578		1.595	1.041-2.445	
HR^(a)			0.001			0.001
Negative	1			1		
Positive	0.539	0.379-0.767		0.518	0.354-0.756	
Her-2			0.987			0.057
Negative	1			1		
Positive	1.003	0.702-1.434		1.543	0.988-1.543	
Tumor size(cm)			0.000			0.010
<2	1			1		
≥2	1.509	1.261-1.806		1.275	1.059-1.535	
Lymph node metastasis			0.000			0.000
no	1			1		
yes	3.612	2.500-5.219		3.261	2.226-4.776	
With Paget's Disease			0.005			0.037
no	1			1		
yes	1.702	1.169-2.479		1.647	1.030-2.639	
Abbreviations: PD: Paget's Disease; HR: Hormone Receptor; HER-2: Human Epidermal Growth Factor Receptor-2;						
(a): HR positive: ER (Estrogen Receptor) positive or/and PR (Progesterone Receptor) positive.						

Discussion:

Since mammary PD was discovered in the 19th century, the mechanism of its pathogenesis has been controversial. To date, there are two mainstream hypotheses of PD origins: epidermotropic and transformation theories [15, 16]. Recently, whole-exome sequencing was performed on paired mammary

PD and BC samples [17]. Distinct gene mutations were detected and explained by independent oncogenic events between the two groups, which might complicate and obscure the association between mammary PD and BC. Meanwhile, for BC patients with PD, there are no specific category data addressing definite management based on version 3.2018 of the current National Comprehensive Cancer Network (NCCN) guidelines (NCCN Guidelines Insights: Breast Cancer, Version 3.2018). Today, PD is not specifically considered, and its treatment is based on the biological characteristics and stage of any underlying cancer and the experience of physicians. Exploring the biological characteristics and clinical prognosis of BC with or without concomitant PD accurately and objectively is the focus of our study.

Based on our study cohort and SEER database, the PD group was older, and its patients tended to have larger tumors and more lymph node metastases than the non-PD group patients did (Table 1 and Table S1). The results suggested that patients diagnosed with mammary PD with underlying invasive cancer would have poor tumor characteristics, which is consistent with a study reported by Wong *et al.* [18]. Part of the reason for this phenomenon could be explained by the relatively rapid progression of PD disease. Hyo Soon *et al.* reported that PD was initially mistaken for skin inflammation and ignored by patients, and most patients came to the clinic with relatively advanced disease [19]. Since 82.0% of PD patients in our cohort had concomitant IDC, PD needs to attract the attention of doctors and patients, and early detection and consultation are very important [19]. In addition, BC patients in the PD group were much more likely to be HR negative and HER-2 positive and to have a high proportion of Ki-67 tumors than BC patients in the non-PD group. Of the four molecular subtypes of BC, HER-2 overexpression accounted for 54% of cases in the PD-IDC group and 8% of cases in the non-PD-IDC group ($P < 0.001$). Since the different molecular subtypes of BC have different risk factors [20], there are also specific risk factors for the development of PD-IDC; however, currently, those factors remain unknown [21].

Worse DFS was observed in the PD group than in the non-PD group, as shown by our cohort and SEER database survival analysis (Fig. 2a, 2b). Univariate and multivariate Cox regression analyses showed that PD was an independent factor influencing DFS (Table 2). Our matched group study also confirmed that PD was an independent poor-risk factor. Several previous series have demonstrated that PD negatively influences BC survival, [18, 22, 23] but few of these previous studies have been based on Asian populations, or they had small sample sizes. Huan *et al.* [4] performed a matched case-control study between 85 Chinese BC patients with PD and a matched group of 85 BC patients without PD and observed poor OS and DFS in the PD group. Our cohort study was based on a natural Chinese cohort with relatively large samples, which might be more reflective of the clinical characteristics of Asian PD patients. In addition, we observed that the OS in our group was better than that in the SEER group, and this phenomenon may be due to the presence of different races with different PD tumor characteristics (Table. S2).

It is interesting to note that more than half of the PD breast cancers were HER-2 overexpression subtypes. Moreover, up to 70.7% of patients in the PD group had HER-2-positive tumors. This is consistent with Wachter *et al.*'s reports, which attracted our attention [21]. However, our univariate and multivariate Cox regression analyses did not consider HER-2 status as a significant prognostic factor. Our matched study

demonstrated that PD was an independent poor-risk factor after balancing HER-2 status. It seems that the worse survival of the PD group was caused by PD's intrinsic features other than HER-2 status. Why the HER-2 overexpression subtype accounts for such a high proportion of cases in the PD group requires further research to explain.

To date, few studies have specifically focused on the relationship between molecular subtype and prognosis as well as anti-Her-2 therapy in mammary PD. We explored the survival prognosis of PD for four different molecular subtypes and found that the DFS of TNBC patients was the worst in the PD-IDC group, while patients with HER-2-overexpressing breast cancer survived best (Fig. 3a, $P=0.045$). Taking anti-Her-2 therapy into account, we divided our PD-IDC group into two groups based on whether or not they received targeted therapy. Interestingly, the good prognosis of HER-2 overexpression breast cancer was only observed in patients who had used targeted therapy (Fig. S3b, c). This result indicated that HER-2-overexpression BC patients with PD could benefit from targeted therapy against Her-2. The Her-2 state has been tested in the SEER database since 2010; consequently, some of the analyses based on the SEER database that spanned the period around 2010 had apparently been limited in their analysis of Her-2 [23], which was why their conclusions somewhat differed from ours.

However, the present study had some limitations. Considering the Her-2 state, our patients were consecutively recruited for this study from 2004-2015, while the SEER database was constructed after 2010. Different time points might influence the strength of our results. Our study may provide a stronger understanding of BC with PD. Prospective clinical studies with larger samples are needed to support these findings.

Declarations:

Ethics approval and consent to participate

This study did not involve animals.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

This retrospective study was approved by the Ethics Committee Review Board of Fudan University Shanghai Cancer Center (050432), and the need to obtain informed consent was waived.

Consent for publication

Not applicable.

Availability of data and materials

The data used in this study are available free of charge online at www.seer.cancer.gov on request.

All data generated or analyzed during this study are included in this published article.

Competing interests

The authors declare no conflict of interest.

Funding

No funding.

Authors' Contributions

All authors read and approved the final manuscript. HL and XH conceived and designed the study. BY H and XL X analyzed the data. XZ Z and BY H contributed reagents, materials, and analysis tools. BY H and HL wrote the main manuscript text. BY H and XL X prepared figures 1-4.

Acknowledgements

Not applicable.

References:

1. Siegel RL, Miller KD, Jemal A: **Cancer statistics, 2020**. *CA Cancer J Clin* 2020, **70**(1):7-30.
2. Wei Fu MD, Vijay K. Mittel, M.D., and Shun C. Young, M.D., F.A.C.S., M.S.A.: **Paget Disease of the Breast Analysis of 41 Patients**. *Am J Clin Oncol* 2001, **24**(4):397–400.
3. Dalberg K, Hellborg H, Warnberg F: **Paget's disease of the nipple in a population based cohort**. *Breast Cancer Res Treat* 2008, **111**(2):313-319.
4. Zhou H, Lu K, Zheng L, Guo L, Gao Y, Miao X, Chen Z, Wang X: **Prognostic significance of mammary Paget's disease in Chinese women: a 10-year, population-based, matched cohort study**. *Onco Targets Ther* 2018, **11**:8319-8326.
5. Lohsiriwat V, Martella S, Rietjens M, Botteri E, Rotmensz N, Mastropasqua MG, Garusi C, De Lorenzi F, Manconi A, Sommario M *et al*: **Paget's disease as a local recurrence after nipple-sparing mastectomy: clinical presentation, treatment, outcome, and risk factor analysis**. *Ann Surg Oncol* 2012, **19**(6):1850-1855.
6. Chen CY, Sun LM, Anderson BO: **Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S**. *Cancer* 2006, **107**(7):1448-1458.
7. Abubakar M, Sung H, Bcr D, Guida J, Tang TS, Pfeiffer RM, Yang XR: **Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population**. *Breast Cancer Res* 2018, **20**(1):114.
8. Deniz M, DeGregorio A, DeGregorio N, Bekes I, Widschwendter P, Schochter F, Ernst K, Scholz C, Bauer EC, Aivazova-Fuchs V *et al*: **Differential prognostic relevance of patho-anatomical factors among**

- different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study.** *Breast* 2019, **44**:81-89.
9. Howlader N, Cronin KA, Kurian AW, Andridge R: **Differences in Breast Cancer Survival by Molecular Subtypes in the United States.** *Cancer Epidemiol Biomarkers Prev* 2018, **27**(6):619-626.
 10. Zuo T, Zeng H, Li H, Liu S, Yang L, Xia C, Zheng R, Ma F, Liu L, Wang N *et al*: **The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study.** *Chin J Cancer* 2017, **36**(1):84.
 11. Munoz DF, Plevritis SK: **Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment.** *Med Decis Making* 2018, **38**(1_suppl):32S-43S.
 12. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD *et al*: **Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.** *J Clin Oncol* 2007, **25**(15):2127-2132.
 13. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Hunt KK: **Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.** *JAMA Oncol* 2019, **5**(1):45-50.
 14. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsy P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ *et al*: **De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.** *Ann Oncol* 2017, **28**(8):1700-1712.
 15. Yim JH: **Underlying Pathology in Mammary Paget's Disease.** *Annals of Surgical Oncology* 1997, **4**(4):287-292.
 16. MICHAEL D. LAGIOS: **Paget's Disease of the Nipple Alternative Management in Cases Without or With Minimal Extent of Underlying Breast Carcinoma** *Cancer* 1984, 1984 Aug 01;**54**(3).
 17. Zhang G, Zhou S, Zhong W, Hong L, Wang Y, Lu S, Pan J, Huang Y, Su M, Crawford R *et al*: **Whole-Exome Sequencing Reveals Frequent Mutations in Chromatin Remodeling Genes in Mammary and Extramammary Paget's Diseases.** *J Invest Dermatol* 2019, **139**(4):789-795.
 18. Wong SM, Freedman RA, Sagara Y, Stamell EF, Desantis SD, Barry WT, Golshan M: **The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma.** *Cancer* 2015, **121**(24):4333-4340.
 19. Hyo Soon Lim MSJJ, MD • Ji Shin Lee, : **Paget Disease of the Breast: Mammographic, US, and MR Imaging Findings with Pathologic Correlation.** *Radiographics* 2011, 2011 Nov-Dec;**31**(7).
 20. Holm J, Eriksson L, Ploner A, Eriksson M, Rantalainen M, Li J, Hall P, Czene K: **Assessment of Breast Cancer Risk Factors Reveals Subtype Heterogeneity.** *Cancer Res* 2017, **77**(13):3708-3717.
 21. Wachter DL, Wachter PW, Fasching PA, Beckmann MW, Hack CC, Riener MO, Hartmann A, Strehl JD: **Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization.** *Arch Pathol Lab Med* 2019, **143**(2):206-211.

22. Muttarak M, Siriya B, Kongmebhol P, Chaiwun B, Sukhamwang N: **Paget's disease of the breast: clinical, imaging and pathologic findings: a review of 16 patients.** *Biomed Imaging Interv J* 2011, 7(2):e16.
23. Chen S, Chen H, Yi Y, Jiang X, Lei H, Luo X, Chen Y, Liu S, Yuan D, Jia X *et al*: **Comparative study of breast cancer with or without concomitant Paget disease: An analysis of the SEER database.** *Cancer Med* 2019, 8(8):4043-4054.

Figures




Figure 1

Molecular subtypes of the PD Group and Non-PD Group of FUSCC, SEER database. 1a. Molecular subtypes of the PD group of FUSCC, n= 333. 1b. Molecular subtypes of the Non-PD Group of FUSCC, n= 1114. 1c. Molecular subtypes of the PD Group of SEER database, n= 444. 1d. Molecular subtypes of the

Non-PD Group of SEER database, n= 253496. The P value was less than 0.001, by using Pearson Chi-square tests to compare the distribution of molecular subtypes in PD group (1a) and Non-PD Group (1b) in FUSCC, demonstrating a difference. The P value was also less than 0.001, by using Pearson Chi-square tests to compare the distribution of molecular subtypes in PD group (1c) and Non-PD Group (1d) in SEER database, demonstrating a difference. PD = Pagets' Disease; ER= Estrogen Receptor; PR= Progesterone Receptor; HER-2= Human Epidermal Growth Factor Receptor-2, HR (Hormone Receptor) +: Either ER or PR+ Luminal A: HR+, HER-2 (-), Ki-67<14%; Luminal B: HR+, HER-2(-), Ki-67≥14% or HR+, HER-2(+); HER-2 Overexpression: HR-,HER-2 (+); TNBC (Triple negative breast cancer): ER (-),PR (-),HER-2 (-). Because the SEER database lacks information on Ki-67, molecular subtypes were replaced by HR(+),HER-2(-),HR(+),HER-2(+),HR(-),HER-2(+),HR(-),HER-2(-).




Figure 2

Kaplan-Meier Survival Curves of patients in PD Group and Non-PD Group of FUSCC, SEER database. 2a. Comparison of DFS of patients in PD Group and Non-PD Group of FUSCC. 2b. Comparison of BCSS of patients in PD Group and Non-PD Group of SEER database. The DFS was estimated between PD Group and Non-PD Group of FUSCC by Log-rank test with a P value of 0.001. The BCSS was estimated between PD Group and Non-PD Group of SEER database by Log-rank test with a P value less than 0.001. PD = Pagets' Disease; DFS=Disease Free Survival; BCSS = Breast Cancer Specific Survival




Figure 3

Kaplan-Meier Survival Curves of PD patients in different subgroups of FUSCC. 3a. Comparison of DFS according four molecular subtypes: Luminal A, Luminal B, HER-2 Overexpression and TNBC. 3b. Disease Free Survival curves of different subgroups before 2010 without anti-HER-2 therapy. 3c. Disease Free Survival curves of different subgroups after 2010 with anti-HER-2 therapy. The DFS of Fig. 3a was estimated by Log-rank test with a P value of 0.045. The DFS of Fig. 3b was estimated by Log-rank test with a P value of 0.300. The DFS of Fig. 3c was estimated by Log-rank test with a P value of 0.068. PD = Pagets' Disease; DFS=Disease Free Survival.

4a.




Figure 4

Kaplan-Meier Survival Curves between PD Group and Non-PD Group (Matched Group) of FUSCC. The DFS was estimated by Log-rank test with a P value of 0.022. PD = Pagets' Disease; DFS=Disease Free Survival.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [HanBYetal.FigureS1.pdf](#)
- [HanBYetal.FigureS2.pdf](#)

- [HanBYetal.FigureS3.pdf](#)
- [HanBYetal.TableS1.xlsx](#)
- [HanBYetal.TableS2.xlsx](#)
- [HanBYetal.Table.S3.xlsx](#)